Given the availability of the anti-CD19 scFv, FMC63, and recent clinical advances in CART-19 therapy, we sought to first explore the efficacy and optimal configuration of GMP-grade CART-19 cells against B-ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.